Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Molecular Targeted Agents /

119 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM1470

    11/05/2014

    Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    VICCTHO1718

    08/17/2017

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder

    VICCURO1723

    08/10/2017

    An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE16126

    08/10/2017

    PHIb Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (MBC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell

    VICCURO16101

    08/10/2017

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Myelodysplastic Syndrome

    VICCHEM16146

    08/07/2017

    A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy with DNA Methyl Transferase Inhibitors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Lung
    Miscellaneous
    Non Small Cell
    Pancreatic
    Rectal
    Small Cell

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM1709

    08/01/2017

    A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE15136

    07/27/2017

    A Phase II Trial of Atezolizumab (Anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Head/Neck

    VICCHN16122

    07/25/2017

    A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin plus Definitive Radiation Therapy) versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    VICCSAR1726

    07/21/2017

    A Randomlzed Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1684

    07/20/2017

    Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM16156

    07/17/2017

    A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

    Molecular Targeted Agents / Immunotherapy / Biologics

    Urologic

    VICCURO1724

    07/10/2017

    A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    VICCSAR1744

    07/10/2017

    A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Miscellaneous

    VICCMD16103

    07/10/2017

    My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

    Molecular Targeted Agents / Immunotherapy / Biologics

    Gynecologic
    Ovarian

    NRGGYNGY004

    06/27/2017

    A Phase III study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent, Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Cervical

    VICCGYN16105

    06/26/2017

    Phase III Study of ADXS11-001 Administered Following Chemoradiation As Adjuvant Treatment For High Risk Locally Advanced Cervical Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Liver

    VICCGI1721

    06/23/2017

    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of AG-120 in Previously-Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1727

    06/15/2017

    A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO16139

    06/13/2017

    A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell

    VICCMD1705

    06/12/2017

    A Phase 1B Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilumumab, Interferon-Alpha or other Immune Modulating Therapies in Patients with Locally Advanced Metastatic Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)

    ECOGUROEA8143

    06/09/2017

    PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

    Molecular Targeted Agents / Immunotherapy / Biologics

    Ovarian

    VICCGYN16132

    06/06/2017

    PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM1656

    06/06/2017

    A Randomized, Multicenter, Open-Label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination with Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (≥ 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Rectal

    VICCGI1665

    06/01/2017

    A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    VICCSAR16155

    05/31/2017

    A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Endocrine
    Lung
    Non Small Cell
    Ovarian

    VICCTHO1722

    05/26/2017

    Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO16148

    05/25/2017

    A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pediatric Leukemia

    VICCPED15111

    05/18/2017

    A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (REVLIMID?) in Pediatric Subjects from 1 to ≤ 18 Years of Age with Relapsed OR Refractory Acute Myeloid Leukemia

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)

    VICCURO16120

    05/15/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM16136

    05/10/2017

    A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCBMT16137

    05/05/2017

    A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM16123

    05/03/2017

    A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    VICCNEU1688

    04/28/2017

    A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (Tumor O6-methylguanine DNA methyltransferase) Glioblastoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    VICCNEU1644

    04/28/2017

    A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Miscellaneous

    VICCPHI16154

    04/25/2017

    Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    VICCTHO1691

    04/25/2017

    A Phase II Single-Arm Trial to Investigate Tepotinib in advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-Doublet-Containing Regimen

    Molecular Targeted Agents / Immunotherapy / Biologics

    Endocrine
    Neuroblastoma (Pediatrics)
    Neuroendocrine

    VICCPED16157

    04/24/2017

    NMTT-Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Miscellaneous

    VICCMD1672

    04/07/2017

    A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors - OLAPCO (OLAParib COmbinations)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pediatric Solid Tumors

    VICCPED1632

    04/04/2017

    A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    ECOGBRES1418

    03/17/2017

    A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN+) After Neoadjuvant Chemotherapy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pancreatic

    ECOGGIS1513

    03/17/2017

    Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic

    VICCBMT16110

    03/10/2017

    A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCGI1679

    03/03/2017

    A Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients with Advanced or Metastatic Adenocarcinoma of the Small Intestine

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)

    VICCURO1653

    03/02/2017

    A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of AVELUMAB (MSB0010718C) in Combination with AXITINIB (INLYTA?) versus SUNITINIB (SUTENT?) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Myelodysplastic Syndrome

    VICCHEM1622

    03/02/2017

    A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions

    Molecular Targeted Agents / Immunotherapy / Biologics

    Miscellaneous

    VICCPHI15149

    02/20/2017

    A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects with Advanced or Recurrent Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pediatric Leukemia

    VICCPED15143

    02/15/2017

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory Bprecursor Acute Lymphoblastic Leukemia (r/r ALL)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Rectal

    NRGGI002

    02/14/2017

    A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE15147

    01/20/2017

    A Randomized Phase II Trial of Fulvestrant with or without Ribociclib (LEE011) After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Advanced Hormone Receptor Positive, HER2 Negative Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    ECOGNEUA221208

    01/18/2017

    Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis after Radiosurgery for Brain Metastases

    Molecular Targeted Agents / Immunotherapy / Biologics

    Miscellaneous

    VICCMD15128

    01/16/2017

    A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

    Molecular Targeted Agents / Immunotherapy / Biologics

    Urologic

    VICCURO1668

    01/11/2017

    A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

    Molecular Targeted Agents / Immunotherapy / Biologics

    Head/Neck
    Lung
    Melanoma
    Non Small Cell

    VICCMD1636

    12/21/2016

    A Phase 1b/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1642

    12/15/2016

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Esophageal
    Gastric/Gastroesophageal

    VICCGI1655

    12/14/2016

    A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Melanoma
    Non Small Cell

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma
    Pediatric Lymphoma
    Pediatric Solid Tumors

    VICCPED1620

    12/08/2016

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    VICCNEU1670

    12/08/2016

    A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy - STELLAR Study

    Molecular Targeted Agents / Immunotherapy / Biologics

    Miscellaneous

    VICCPHI1682

    11/17/2016

    An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013 (Pan-HER), a Monoclonal Antibody Mixture Targeting EGFR, HER2 and HER3, in Patients with Advanced Epithelial Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1640

    11/10/2016

    PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Neuroendocrine

    VICCTHO15115

    11/08/2016

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120 Mg Plus Bsc Vs. Placebo Plus Bsc For Tumor Control In Subjects With Well Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Ovarian
    Uterine

    VICCPHI1676

    11/04/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Liver

    VICCMD15133

    10/06/2016

    A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic
    Leukemia
    Lymphoma

    VICCBMT1610

    09/30/2016

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Lymphoma

    VICCBMT1651

    09/30/2016

    Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

    Molecular Targeted Agents / Immunotherapy / Biologics

    Gastric/Gastroesophageal
    Liver
    Lung

    VICCPHI15114

    09/28/2016

    An Open-Label, Multicenter, Phase 1 study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Myelodysplastic Syndrome

    VICCHEM1660

    09/27/2016

    A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Multiple Myeloma

    VICCHEM1621

    09/16/2016

    An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Uterine

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE15120

    08/18/2016

    Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor-Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamic Markers (TBCRC035)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma
    Miscellaneous

    VICCPHI1616

    06/08/2016

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Molecular Targeted Agents / Immunotherapy / Biologics

    Kidney (Renal Cell)

    VICCURO15127

    06/01/2016

    A Randomized Phase 2 Trial of AXITINIB and TRC105 versus AXITINIB Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Colon
    Gastric/Gastroesophageal
    Kidney (Renal Cell)
    Rectal
    Urologic

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Pediatric Leukemia

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Head/Neck
    Liver
    Lung
    Miscellaneous
    Neuro-Oncology
    Rectal
    Sarcoma
    Thyroid

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Head/Neck

    VICCHN1574

    03/21/2016

    A Randomized, Multicenter, Double-Blind Phase 2 Study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus -Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1557

    03/11/2016

    A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Pediatric Leukemia

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM15112

    01/11/2016

    A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications

    Molecular Targeted Agents / Immunotherapy / Biologics

    Gastric/Gastroesophageal

    VICCGI1515

    01/05/2016

    A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuro-Oncology

    ECOGNEUA071401

    12/18/2015

    Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1546

    12/01/2015

    The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Breast
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Gynecologic
    Head/Neck
    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell
    Pancreatic
    Rectal
    Urologic
    Uterine

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Multiple Myeloma

    VICCHEM14131

    11/17/2015

    Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    VICCBRE1692

    09/01/2015

    Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

    Molecular Targeted Agents / Immunotherapy / Biologics

    Other

    ECOGEAY131-M

    07/16/2015

    Molecular Analysis for Therapy Choice

    Molecular Targeted Agents / Immunotherapy / Biologics

    Pediatric Lymphoma

    COGAHOD1331

    07/15/2015

    A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Small Cell

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Soft Tissue

    COGARST1321

    04/21/2015

    Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND# 118613)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Sarcoma

    VICCSAR1483

    02/26/2015

    SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma

    VICCMEL1471

    02/04/2015

    A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Melanoma

    VICCMEL1457

    01/19/2015

    A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCPHI1436

    08/18/2014

    A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Leukemia

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

    Molecular Targeted Agents / Immunotherapy / Biologics

    VICCPHI1435

    07/31/2014

    First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced Stage Solid Tumors

    Molecular Targeted Agents / Immunotherapy / Biologics

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast - Female
    Breast - Male

    ECOGBRES1207

    10/31/2013

    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lymphoma

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lymphoma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Neuroblastoma (Pediatrics)
    Pediatric Solid Tumors

    VICCPED1249

    08/06/2012

    An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung
    Non Small Cell

    VICCTHN1244

    07/25/2012

    Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    CTSUBRENB-43-M

    04/26/2012

    A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

    Molecular Targeted Agents / Immunotherapy / Biologics

    Breast

    CTSUNSABPBREB-47-M

    04/26/2012

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

    Molecular Targeted Agents / Immunotherapy / Biologics

    Non Small Cell

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Molecular Targeted Agents / Immunotherapy / Biologics

    Liver

    CTSUGIC80802-M

    12/07/2010

    Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

    Molecular Targeted Agents / Immunotherapy / Biologics

    Lung

    CTSUTHOC30607-M

    02/17/2010

    ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Head/Neck

    ECOGHNE1305-M

    02/11/2009

    A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

    Molecular Targeted Agents / Immunotherapy / Biologics

    Non Small Cell

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor